论文部分内容阅读
目的 研究153 钐 -乙二胺四甲撑磷酸 (153 Sm EDTMP)与化疗药物联合治疗肺癌骨转移的临床效果。方法 110例肺癌已有骨转移而未作手术的患者接受了该治疗 ,其中男 82例 ,女 2 8例 ,年龄 3 2～76岁 ;原发癌分别为肺鳞癌 2 8例 ,肺腺癌 2 7例 ,小细胞肺癌 7例 ,混合型 41例 ,肺泡癌 7例。 110例中 ,单独用153 Sm治疗 3 7例 ,153 Sm治疗后 3天加化疗 42例 ,化疗完成后 3 0天再加153 Sm治疗 3 1例。153 Sm EDTMP采用两次给药法 ,其剂量的范围为 1111～ 2 660MBq。小细胞肺癌用CCNU、MTX、CTX化疗方案 ;非小细胞肺癌用MMC、VCR、DDP方案。资料用卡方检验作统计分析。结果 单独153 Sm治疗者的总止痛有效率为89 .2 % ,153 Sm加化疗为 92 .8% ,化疗后加153 Sm为 90 .3 %。单独153 Sm治疗者病灶消失 9例 ,153 Sm加化疗消失 12例 ,化疗后加153 Sm消失 9例。单独153 Sm治疗者 1年生存率为 2 9.7% (11/ 3 7) ,153 Sm加化疗为 40 .5 %(17/ 42 ) ,化疗后加153 Sm为 3 8.7% (12 / 3 1)。结论 用153 Sm EDTMP联合化疗治疗肺癌骨转移有较好的临床效果。
Objective To investigate the clinical effect of 153 samarium-ethylenediamine tetramethylene phosphonate (153 Sm EDTMP) in combination with chemotherapeutic agents in the treatment of bone metastases of lung cancer. Methods Totally 110 patients with lung cancer who underwent bone metastasis without surgery were enrolled. Among them, 82 were male and 28 were female, ranging in age from 32 to 76 years. The primary cancers were squamous cell carcinoma of the lung, 28 27 cases of cancer, 7 cases of small cell lung cancer, 41 cases of mixed type, 7 cases of alveolar carcinoma. In 110 cases, 153 cases were treated with 153 Sm alone, 42 cases were treated with 153 Sm three days after chemotherapy, and 31 cases were treated with 153 Sm 30 days after the completion of chemotherapy. The dose of 153 Sm EDTMP was administered twice and the dose range was 1111-2 660 MBq. Small cell lung cancer with CCNU, MTX, CTX chemotherapy; non-small cell lung cancer with MMC, VCR, DDP program. Data using Chi-square test for statistical analysis. Results The total effective analgesia of 153 Sm treatment alone was 89.2%, that of 153 Sm plus chemotherapy was 92.8%, and that of 153 Sm was 90.3% after chemotherapy. In the 153 Sm treatment alone, the lesions disappeared in 9 cases, 153 Sm plus chemotherapy disappeared in 12 cases, and 153 Sm disappeared after chemotherapy in 9 cases. The 1-year survival rate of 153 Sm patients alone was 2 9.7% (11/3 7), 153 Sm plus chemotherapy was 40.5% (17/42), 153 Sm was 37.7% (12/3 1) after chemotherapy, . Conclusion 153 Sm EDTMP combined with chemotherapy for the treatment of bone metastases of lung cancer has a good clinical effect.